This trial is evaluating whether FOR46 will improve 3 primary outcomes and 7 secondary outcomes in patients with Prostate Cancer. Measurement will happen over the course of Up to 3 weeks.
This trial requires 36 total participants across 2 different treatment groups
This trial involves 2 different treatments. FOR46 is the primary treatment being studied. Participants will be divided into 2 treatment groups. There is no placebo group. The treatments being tested are in Phase 1 & 2 and have already been tested with other people.
"Based on this analysis, the majority of PCa cases are diagnosed at ages 60 years or older. This fact suggests that prostate cancer prevention programs should focus on men aged 60 years or older. Furthermore, the fact that half of PCa cases were diagnosed at ages 55 or younger indicates that men of this age group have many more options for prevention and treatment than men over 60 years old." - Anonymous Online Contributor
"Patients with prostate cancer receive a multitude of treatment options. Consideration of many factors, including age, comorbidities, and health issues, is required before selecting the best treatment option." - Anonymous Online Contributor
"Data from a recent study shows that adjuvant treatment of localized prostate cancer can improve survival rates. Chemotherapy appears to increase survival compared to surgery alone. Preoperative brachytherapy does not seem to have an influence on survival rate. Patients treated with hormonal therapy and brachytherapy did not achieve any further improvement in survival." - Anonymous Online Contributor
"The number of prostate cancers diagnosed each year is expected to rise over the next few years. In this article, we discuss the current knowledge about prostate cancers, including its symptoms, aggressiveness, treatment and prognosis. We also describe how current technologies are being applied to establish expectations for the future." - Anonymous Online Contributor
"Findings from a recent study demonstrates the efficacy of tamsulosin as an add-on treatment with finasteride in improving the urinary symptoms of BPH. In addition, it was found that regardless of the baseline severity of the prostate disease (i.e. nocturia, urgency/incontinence), tamsulosin improved the quality of life in all patients." - Anonymous Online Contributor
"Recent findings suggests that there are no differences between the risk of death or major adverse events associated with using F46 compared to conventional treatment. Recent findings support current guidelines recommending that F46 should be offered when treating early stage prostate cancer in men with normal functioning kidneys who receive radiotherapy alone." - Anonymous Online Contributor
"Current research includes drug discovery, biomarker development, and treatment strategies for prostate cancer. At the same time, the literature contains many articles on the genetics of prostate cancer." - Anonymous Online Contributor
"Results from a recent paper indicate that treatment with for46 reduces or prevents development of late effects after radiation therapy for prostate cancer. More importantly, it may also provide a means of reducing the side effects of radiotherapy itself. This trial was registered at clinicaltrials.gov as NCT00441848." - Anonymous Online Contributor
"Patients with low risk disease may benefit from adjuvant therapies. However, for patients requiring curative therapy it remains unclear whether they have an improved survival. Although many patients will benefit from adjuvant therapy, only a minority are likely to receive this treatment because most patients undergoing radical prostatectomy do not require it. Data from a recent study suggests that informing these patients about the uncertainties associated with their decision would help them make a more informed choice." - Anonymous Online Contributor
"The number of new PCa cases detected annually in the U.S. has increased since 1990 and continues to grow each year. This supports the hypothesis that there is an increasing incidence rate for PCa and an increasing prevalence of PCa. Furthermore, age at diagnosis appears to be decreasing over time." - Anonymous Online Contributor
"Based on these findings, it appears that 46,XY karyotype should be considered when evaluating patients with FHH, especially in situations where a child's sex assignment is contemplated and in patients who present with signs of hypogonadism; however, the addition of a routine gonadal assessment is not necessary." - Anonymous Online Contributor